Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
about
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.Systemic Mastocytosis with Associated Chronic Lymphocytic Leukemia: A Matter of Diseases or Prognostic Factors?The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.SOHO State-of-the-Art Update and Next Questions: MPN.
P2860
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Splenomegaly, elevated alkalin ...... ts with systemic mastocytosis.
@en
Splenomegaly, elevated alkalin ...... ts with systemic mastocytosis.
@nl
type
label
Splenomegaly, elevated alkalin ...... ts with systemic mastocytosis.
@en
Splenomegaly, elevated alkalin ...... ts with systemic mastocytosis.
@nl
prefLabel
Splenomegaly, elevated alkalin ...... ts with systemic mastocytosis.
@en
Splenomegaly, elevated alkalin ...... ts with systemic mastocytosis.
@nl
P2093
P2860
P356
P1433
P1476
Splenomegaly, elevated alkalin ...... nts with systemic mastocytosis
@en
P2093
A Fabarius
D Hausmann
G Metzgeroth
P2860
P2888
P304
P356
10.1038/LEU.2016.190
P577
2016-07-15T00:00:00Z